Ibritumomab tiuxetan clinical trials
Also written Zevalin and IDEC-Y2B8.
How each study uses ibritumomab tiuxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 19 Feb 2002 · ZEVALIN · BLA 125019 (FDA, Drugs@FDA)
- European Union
- 16 Jan 2004 · Zevalin · EMEA/H/C/000547 (EMA; now lapsed)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2006 (9)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 9 |
| 2007 | 9 |
| 2008 | 4 |
| 2012 | 3 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 37
M.D. Anderson Cancer Center (7) · Biogen (2) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (2) · Bayer (2) · Spectrum Pharmaceuticals, Inc (2) · Fondazione Italiana Linfomi - ETS (1) · SWOG Cancer Research Network (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Rituximab (10) · Fludarabine (2) · Mitoxantrone (2) · Yttrium Y-90 ibritumomab tiuxetan (2) · Bortezomib (2) · Patient Observation (1) · Maintenance Therapy (1) · Dexamethasone (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
- Yttrium Y-90 ibritumomab tiuxetan is a conjugate made from it, counted on its own page source
Studies
Open first, then newest update. How each study uses ibritumomab tiuxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 45
- Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's LymphomaCompletedPhase 4BiogenNCT00168727Written as ibritumomab tiuxetan (Zevalin®)How we know
- Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaStatus unknownPhase 2Joseph TuscanoNCT01811368Written as ibritumomab tiuxetanHow we know
- Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasCompletedPhase 2M.D. Anderson Cancer CenterNCT00493467Written as Ibritumomab Tiuxetan (Zevalin)How we know
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular LymphomaCompletedPhase 3Fondazione Italiana Linfomi - ETSNCT02063685Written as Ibritumomab Tiuxetan + MaintenanceHow we know
- Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00290511Written as ZevalinHow we know
- Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT00322218Written as ZevalinHow we know
- S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's LymphomaCompletedPhase 2SWOG Cancer Research NetworkNCT00070018Written as Yttrium-90 ibritumomab tiuxetanHow we know
- Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)TerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01662102Written as ZevalinHow we know
- Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationCompletedPhase 2M.D. Anderson Cancer CenterNCT00591630Written as ZevalinHow we know
- Zevalin-beam for Aggressive LymphomaCompletedPhase 3Sheba Medical CenterNCT00491491Written as ibritumomab tiuxetanHow we know
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedPhase 2M.D. Anderson Cancer CenterNCT01490723Written as 111In IbritumomabHow we know
- ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)CompletedPhase 2PETHEMA FoundationNCT00662948Written as Ibritumomab tiuxetanHow we know
- Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceTerminatedPhase 2University of Wisconsin, MadisonNCT00582166Written as Ibritumomab Tiuxetan (Zevalin) + RituximabHow we know
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaTerminatedPhase 1/2Northwestern UniversityNCT00372905Written as Ibritumomab tiuxetanHow we know
- Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedPhase 1Swiss Group for Clinical Cancer ResearchNCT00392691Written as ibritumomab tiuxetanHow we know
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00012298Written as yttrium Y 90 ibritumomab tiuxetanHow we know
- Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)CompletedPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT00644371Written as Ibritumomab Tiuxetan (Zevalin)How we know
- Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)CompletedPhase 2University Hospital, BordeauxNCT00607854Written as Ibritumomab Tiuxetan (Zevalin)How we know
- Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular LymphomaCompletedPhase 2Sunnybrook Health Sciences CentreNCT01446562Written as Y90 Ibritumomab Tiuxetan RITHow we know
- Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse LymphomCompletedPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT00646750Written as Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)How we know
See all 45 studies that test ibritumomab tiuxetan →
Given beside what is tested · 3 — ibritumomab tiuxetan is usual care or a partner of the new treatment
- Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedPhase 3Spectrum Pharmaceuticals, IncNCT01510184Written as ZevalinHow we know
- Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT01549886Written as Y-90-ZevalinHow we know
- Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) TherapyCompletedPhase 2University of BolognaNCT00850512Written as ZevalinHow we know
Codes
What other systems call ibritumomab tiuxetan · ClinicalTrials.gg INT004320
- MeSH (NLM) C422802ibritumomab tiuxetanOne source NLM
- UNII (FDA) 4Q52C550XKIBRITUMOMAB TIUXETANConfirmed FDA, NLM, Wikidata
- RxNorm 262323Confirmed FDA, Wikidata
- Wikidata Q635415ibritumomabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29981Ibritumomab TiuxetanConfirmed FDA, Wikidata
- DrugBank DB00078One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C422802 | ibritumomab tiuxetan | One source NLM |
| UNII (FDA) | 4Q52C550XK | IBRITUMOMAB TIUXETAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 262323 | — | Confirmed FDA, Wikidata |
| Wikidata | Q635415 | ibritumomab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29981 | Ibritumomab Tiuxetan | Confirmed FDA, Wikidata |
| DrugBank | DB00078 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.